Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis

OBJECTIVES: Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study descri...

Descripción completa

Detalles Bibliográficos
Autores principales: den Braanker, Hannah, Wervers, Kim, Mus, Adriana M C, Bangoer, Priyanka S, Davelaar, Nadine, Luime, Jolanda, Tchetverikov, Ilja, Hazes, J M W, Vis, Marijn, Lubberts, Erik, Kok, Marc R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425114/
https://www.ncbi.nlm.nih.gov/pubmed/32669451
http://dx.doi.org/10.1136/rmdopen-2020-001175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425114/
https://www.ncbi.nlm.nih.gov/pubmed/32669451
http://dx.doi.org/10.1136/rmdopen-2020-001175

Ejemplares similares